Yang et al. have shown that temsirolimus (mTORC1 inhibitor) in combination with dactolisib (dual PI3K-mTOR inhibitor) or ZSTK474 (pan-PI3K inhibitor) can collectively inhibit cancer cell growth and overcome cellular resistance to temsirolimus [74]. The gene discussed is PIK3CA; the disease is cancer.